Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)?

Viatris Inc. recently secured approval in Japan for Effexor SR capsules as the first treatment for generalized anxiety disorder (GAD), expanding its market beyond depression. This move aligns with Viatris’s strategy to pivot towards higher-value, innovative medicines from commoditized generics, reinforcing its investment narrative for gradually improving earnings. While promising, this approval alone doesn’t shift the immediate focus on cost savings and managing margin pressures in its core generics business.